Conv. Plasma
Nigella Sativa
Peg.. Lambda

All ivermectin studies
Meta analysis
Home COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Time to clinical respons.. 6% primary Improvement Relative Risk Ivermectin for COVID-19  Roy et al.  EARLY TREATMENT Is early treatment with ivermectin + doxycycline beneficial for COVID-19? Retrospective 29 patients in India No significant difference in recovery Roy et al., medRxiv, March 2021 Favors ivermectin Favors control

Outcome of Different Therapeutic Interventions in Mild COVID-19 Patients in a Single OPD Clinic of West Bengal: A Retrospective study

Roy et al., medRxiv, doi:10.1101/2021.03.08.21252883
Mar 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective database analysis of 56 mild COVID-19 patients, all treated with vitamin C, vitamin D, and zinc, comparing ivermectin + doxycycline (n=14), AZ (n=13), HCQ (n=14), and SOC (n=15), finding that all groups recover quickly, and there was no significant difference between the groups. Subject to the usual limitation of a database study, very small size, and limited evaluation of patients.
This is the 43rd of 99 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 2 sextillion). 46 studies are RCTs, which show efficacy with p=0.00000014. This study is excluded in the after exclusion results of meta analysis: no serious outcomes reported and fast recovery in treatment and control groups, there is little room for a treatment to improve results.
This study includes HCQ and ivermectin.
relative time to clinical response of wellbeing, 5.6% lower, relative time 0.94, p = 0.87, treatment 14, control 15, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Roy et al., 12 Mar 2021, retrospective, database analysis, India, preprint, 5 authors, dosage not specified, this trial uses multiple treatments in the treatment arm (combined with doxycycline) - results of individual treatments may vary.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Outcome of Different Therapeutic Interventions in Mild COVID-19 Patients in a Single OPD Clinic of West Bengal: A Retrospective study
Dr Sayak Roy, Shambo Samrat Samajdar, Santanu K Tripathi, Shatavisa Mukherjee, Kingshuk Bhattacharjee
Introduction: With over 87,273,380 cases being reported and 1,899,440 deaths worldwide as of 9th January 2021, Coronavirus disease 2019 (COVID-19) has become the worst-hit pandemic till date. Every day clinicians are bombarded with many new treatment options that claim to be better than the others.
Ahmed, Karim, Ross, A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis
Ciccullo, Borghetti, Dal Verme, Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line, Int J Antimicrob Agents
Healthworld, COVID-19: Health Ministry issues revised home isolation guidelines
Janowitz, Gablenz, Pattinson, Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series, Gut
Liu, Cao, Xu, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov
Ncid, None
Oldenburg, Doan, Azithromycin for severe COVID-19, Lancet
Roy, Journey So Far With COVID 19 -A Comprehensive Review, European Journal Of Clinical And Experimental Medicine
Roy, Mainakmukhopadhyay, Ventricular arrhythmia risk based on ethnicity in COVID-19 patients on hydroxychloroquine and azithromycin combination: Viewpoint, SN Compr Clin Med
Ruan, Yang, Wang, Jiang, Song, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China, Intensive Care Med
Summary, Therapeutic management of patients with COVID-19
Velavan, Meyer, Mild versus severe COVID-19: Laboratory markers, Int J Infect Dis
Who, None
Wu, Liu, Yang, Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharm Sin B
Zamanian, Pollack, Jr, Gentile, Outpatient inhaled nitric oxide in a patient with vasoreactive idiopathic pulmonary arterial hypertension and COVID-19 infection, Am J Respir Crit Care Med
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop